Vintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Posaconazole | The metabolism of Vintafolide can be decreased when combined with Posaconazole. |
| Voriconazole | The metabolism of Vintafolide can be decreased when combined with Voriconazole. |
| Lopinavir | The serum concentration of Vintafolide can be increased when it is combined with Lopinavir. |
| Erythromycin | The serum concentration of Vintafolide can be increased when it is combined with Erythromycin. |
| Sirolimus | The serum concentration of Vintafolide can be increased when it is combined with Sirolimus. |
| Dirithromycin | The serum concentration of Vintafolide can be increased when it is combined with Dirithromycin. |
| Telithromycin | The serum concentration of Vintafolide can be increased when it is combined with Telithromycin. |
| Candicidin | The serum concentration of Vintafolide can be increased when it is combined with Candicidin. |
| Clarithromycin | The serum concentration of Vintafolide can be increased when it is combined with Clarithromycin. |
| Josamycin | The serum concentration of Vintafolide can be increased when it is combined with Josamycin. |
| Everolimus | The serum concentration of Vintafolide can be increased when it is combined with Everolimus. |
| Epothilone D | The serum concentration of Vintafolide can be increased when it is combined with Epothilone D. |
| Patupilone | The serum concentration of Vintafolide can be increased when it is combined with Patupilone. |
| 6-Deoxyerythronolide B | The serum concentration of Vintafolide can be increased when it is combined with 6-Deoxyerythronolide B. |
| Ixabepilone | The serum concentration of Vintafolide can be increased when it is combined with Ixabepilone. |
| KOS-1584 | The serum concentration of Vintafolide can be increased when it is combined with KOS-1584. |
| Ridaforolimus | The serum concentration of Vintafolide can be increased when it is combined with Ridaforolimus. |
| Temsirolimus | The serum concentration of Vintafolide can be increased when it is combined with Temsirolimus. |
| AVE9633 | The serum concentration of Vintafolide can be increased when it is combined with AVE9633. |
| Coltuximab ravtansine | The serum concentration of Vintafolide can be increased when it is combined with Coltuximab ravtansine. |
| Cethromycin | The serum concentration of Vintafolide can be increased when it is combined with Cethromycin. |
| Mitemcinal | The serum concentration of Vintafolide can be increased when it is combined with Mitemcinal. |
| Brefeldin A | The serum concentration of Vintafolide can be increased when it is combined with Brefeldin A. |
| Solithromycin | The serum concentration of Vintafolide can be increased when it is combined with Solithromycin. |
| Kitasamycin | The serum concentration of Vintafolide can be increased when it is combined with Kitasamycin. |
| Carbomycin | The serum concentration of Vintafolide can be increased when it is combined with Carbomycin. |
| Doramectin | The serum concentration of Vintafolide can be increased when it is combined with Doramectin. |
| Eprinomectin | The serum concentration of Vintafolide can be increased when it is combined with Eprinomectin. |
| Oleandomycin | The serum concentration of Vintafolide can be increased when it is combined with Oleandomycin. |
| Selamectin | The serum concentration of Vintafolide can be increased when it is combined with Selamectin. |
| Tildipirosin | The serum concentration of Vintafolide can be increased when it is combined with Tildipirosin. |
| Tilmicosin | The serum concentration of Vintafolide can be increased when it is combined with Tilmicosin. |
| Tylosin | The serum concentration of Vintafolide can be increased when it is combined with Tylosin. |
| Tylvalosin | The serum concentration of Vintafolide can be increased when it is combined with Tylvalosin. |
| Bryostatin 1 | The serum concentration of Vintafolide can be increased when it is combined with Bryostatin 1. |
| Lorvotuzumab mertansine | The serum concentration of Vintafolide can be increased when it is combined with Lorvotuzumab mertansine. |
| Epofolate | The serum concentration of Vintafolide can be increased when it is combined with Epofolate. |
| Sagopilone | The serum concentration of Vintafolide can be increased when it is combined with Sagopilone. |
| Troleandomycin | The serum concentration of Vintafolide can be increased when it is combined with Troleandomycin. |
| Miocamycin | The serum concentration of Vintafolide can be increased when it is combined with Miocamycin. |
| Flurithromycin | The serum concentration of Vintafolide can be increased when it is combined with Flurithromycin. |
| Rokitamycin | The serum concentration of Vintafolide can be increased when it is combined with Rokitamycin. |
| Midecamycin | The serum concentration of Vintafolide can be increased when it is combined with Midecamycin. |
| Clindamycin | The serum concentration of Vintafolide can be increased when it is combined with Clindamycin. |
| Mepartricin | The serum concentration of Vintafolide can be increased when it is combined with Mepartricin. |
| Mitomycin | The risk or severity of bronchospasm, shortness of breath, and dyspnea can be increased when Vintafolide is combined with Mitomycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vintafolide. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vintafolide. |
| Pegfilgrastim | The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vintafolide. |
| Sargramostim | The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vintafolide. |
| Filgrastim | The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vintafolide. |
| Romiplostim | The risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vintafolide. |
| Regramostim | The risk or severity of peripheral neuropathy can be increased when Regramostim is combined with Vintafolide. |
| Maxy-G34 | The risk or severity of peripheral neuropathy can be increased when Maxy-G34 is combined with Vintafolide. |
| Thrombopoietin | The risk or severity of peripheral neuropathy can be increased when Thrombopoietin is combined with Vintafolide. |
| Ancestim | The risk or severity of peripheral neuropathy can be increased when Ancestim is combined with Vintafolide. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vintafolide. |
| Epoetin delta | The risk or severity of peripheral neuropathy can be increased when Epoetin delta is combined with Vintafolide. |
| Muplestim | The risk or severity of peripheral neuropathy can be increased when Muplestim is combined with Vintafolide. |
| Balugrastim | The risk or severity of peripheral neuropathy can be increased when Balugrastim is combined with Vintafolide. |
| Lenograstim | The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vintafolide. |
| Lipegfilgrastim | The risk or severity of peripheral neuropathy can be increased when Lipegfilgrastim is combined with Vintafolide. |
| Leridistim | The risk or severity of peripheral neuropathy can be increased when Leridistim is combined with Vintafolide. |
| Pegteograstim | The risk or severity of peripheral neuropathy can be increased when Pegteograstim is combined with Vintafolide. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Vintafolide. |
| Eflapegrastim | The risk or severity of peripheral neuropathy can be increased when Eflapegrastim is combined with Vintafolide. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Vintafolide. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Vintafolide is combined with Ambroxol. |